Angel signs new contract with ReNeuron (3954D)
16 5월 2012 - 3:00PM
UK Regulatory
TIDMABH
RNS Number : 3954D
Angel Biotechnology Holdings Plc
16 May 2012
16 May 2012
Angel Biotechnology Holdings plc
("Angel" or "the Company")
Angel signs new contract with ReNeuron to provide GMP cell
manufacturing services for completion of stroke clinical trial
Angel Biotechnology Holdings plc, (AIM:ABH), the
biopharmaceutical contract manufacturer, has signed a new contract
with ReNeuron Group plc (AIM:RENE) to perform GMP manufacturing
services in support of the final part of the PISCES Phase 1
clinical trial of its ReN001 stem cell therapy for stroke; the
value of the contract was not disclosed.
Dr Stewart White, Acting CEO, Angel Biotechnology said: "Angel
is very proud to be providing ReNeuron with additional
manufacturing support to complete this ground breaking Phase 1
clinical trial. This contract is further recognition of the strong
partnership between Angel and ReNeuron, and also reaffirms both
companies commitment to provide solutions for a real clinical
need."
For further information:
Angel Biotechnology Holdings plc
Lorna Peers, Finance Director +44 (0) 131 445 6077
Stewart White, Acting CEO/Commercial Director
www.angelbio.com
Grant Thornton, Corporate Finance
Colin Aaronson / Melanie Frean +44 (0) 20 7383 5100
Hybridan LLP (Broker)
Claire Noyce, Deepak Reddy +44 (0) 20 7947 4350
Media enquiries:
The Communications Portfolio Ltd
Ariane Comstive / Caolan Mahon +44 (0) 20 7536 2028 / 2029
ariane.comstive@communications-portfolio.co.uk
Notes to Editors:
Angel Biotechnology Holdings plc is a full service contract
bio-manufacturing partner to biotechnology and pharmaceutical
companies worldwide. Angel specialises in advanced biologics
including biopharmaceutical proteins and cell therapies, such as
cellular vaccines and stem cells. At present, Angel's products are
principally used in pre-clinical studies and clinical trials with a
view to becoming the contract manufacturer of choice on a
continuing basis.
Drug development companies outsource their biopharmaceutical
manufacturing requirements to Angel to reduce their own capital
requirements and enable them to develop products more rapidly. In
addition, Angel provides complete regulatory services and
documentation to its customers while its manufacturing processes
adhere to the most stringent regulatory requirements. Products are
produced to current Good Manufacturing Practice (cGMP) standards as
required by the US Food and Drug Administration (FDA), and in
facilities that are certified to European standards by the
Medicines and Healthcare products Regulatory Agency (MHRA).
Its customers range from early-stage biotechnology companies
including ReNeuron plc and US-based Pathfinder Cell Therapy, to
established pharmaceutical companies such as Russian-based Materia
Medica Holdings.
Angel has three facilities: Pentlands Science Park near
Edinburgh where it employs 38 people, a site in Cramlington, near
Newcastle-upon-Tyne, which is expected to employ up to 10 people by
the end of 2012 and Angel Biomedical Ltd based in Nova Technology
Park, Glasgow.
More information is available at www.angelbio.com .
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMGMKFKLGZZM
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Angel Biotechnology (LSE:ABH)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024